ArticleCurrent oncology (Toronto, Ont.)2026
Impact of High-Risk Mutations and Treatment Intensity in Accelerated-Phase Blast-Phase MPN Without Adverse-Risk Karyotype and TP53.
Verna Cheung et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.